INM Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	476 022
Vidutinė apimtis	382 840
Rinkos kapitalizacija	1.39M
EPS	$0 ( 2024-02-16 )
Kita pelno data	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.550
ATR14	$0.00400 (1.74%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-14	Hull Andrew	Sell	42	Employee Stock Option (Expiration)
2024-03-04	Hsu Eric C	Sell	309	Employee Stock Option (Expiration)
2024-01-21	Mancini Alexandra Diane Janet	Sell	121	Employee Stock Option (Expiration)
2024-02-20	Jagpal Netta	Sell	50 000	Employee Stock Option (Right to Buy)
2024-02-21	Hull Andrew	Buy	37 500	Common Stock

INSIDER POWER
74.61
Last 93 transactions
Buy: 1 291 573 \| Sell: 391 310

Tūris Koreliacija

Ilgas: -0.25 (neutral)

Trumpas: 0.53 (weak)

Signal:(43.503) Neutral

InMed Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
ZSAN	0.901
KBSF	0.889
BNOX	0.885
ARQQ	0.884
AYLA	0.884
VIH	0.884
LYRA	0.882
QLGN	0.881
LQDT	0.879
DWACU	0.87

10 Labiausiai neigiamai susiję koreliacijos
STAY	-0.89
AVGO	-0.884
TIPT	-0.883
BNIXU	-0.876
TVTY	-0.875
ARDX	-0.874
USLM	-0.872
LRFC	-0.869
LUNA	-0.864
PEBK	-0.862

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

InMed Pharmaceuticals Koreliacija - Valiuta/Žaliavos

0.00
( neutral )

0.43
( neutral )

0.00
( neutral )

0.10
( neutral )

InMed Pharmaceuticals Finansinės ataskaitos

Annual	2023
Pajamos:	$4.14M
Bruto pelnas:	$1.40M (33.93 %)
EPS:	$-3.25

FY	2023
Pajamos:	$4.14M
Bruto pelnas:	$1.40M (33.93 %)
EPS:	$-3.25

FY	2022
Pajamos:	$1.09M
Bruto pelnas:	$543 546 (49.89 %)
EPS:	$-41.74

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-38.00

Financial Reports:

No articles found.

InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.